EQT agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) in cash, setting up the life-sciences tools and diagnostics maker to go private following a review by Qiagen boards. The transaction follows years of on-and-off takeover interest and an extended strategic review described by the company as focusing on its next growth phase. Qiagen said the boards unanimously concluded that a buyout by EQT offers the best path forward, combining operational flexibility with longer-term investment room. EQT’s structure includes indirect participation from co-investors including Luxinva (Abu Dhabi Investment Authority) and CPP Investments, with Qiagen continuing to operate under its current name until the offer closes. Qiagen’s management also signaled an intent to keep R&D and customer relationships intact during the transition. For biotech suppliers and diagnostic labs, a private Qiagen could shift capital-allocation priorities and product roadmaps—particularly around workflow solutions—while the near-term focus remains on closing mechanics and shareholder approvals.